Skip to main content
Top
Published in: Abdominal Radiology 8/2016

01-08-2016

Role of contrast-enhanced ultrasound (CEUS) in evaluation of thermal ablation zone

Authors: Ilya Lekht, Mittul Gulati, Megha Nayyar, Michael D. Katz, Ramon Ter-Oganesyan, Mary Marx, Steven Y. Cen, Edward Grant

Published in: Abdominal Radiology | Issue 8/2016

Login to get access

Purpose

Thermal ablation has emerged as a mainstay therapy for primary and metastatic liver malignancy. Percutaneous thermal ablation is usually performed under CT and/or ultrasound guidance. CT guidance frequently utilizes iodinated contrast for tumor targeting, with additional radiation and contrast required at the end of the procedure to ensure satisfactory ablation margins. Contrast-enhanced ultrasound (CEUS) is an imaging technique utilizing microbubble contrast agents to demonstrate blood flow and tissue perfusion. In this study, we performed a retrospective review to assess the utility of CEUS in the immediate post ablation detection of residual tumor.

Methods

Sixty-four ablations were retrospectively reviewed. 6/64 ablations (9.4%) had residual tumor on the first follow-up imaging after thermal ablation. There were two groups of patients. Group 1 underwent standard protocol thermal ablation with CT and/or ultrasound guidance. Group 2 not only had thermal ablation with a protocol identical to group 1, but also had CEUS assessment at the conclusion of the procedure to ensure satisfactory ablation zone.

Results

The residual tumor rate in group 1 was 16.7% and the residual tumor rate in group 2 was 0%. The difference between the groups was statistically significant with a p value of 0.023. The results suggest that using CEUS assessment immediately after the ablation procedure reduces the rate of residual tumor after thermal ablation.

Conclusion

CEUS evaluation at the end of an ablation procedure is a powerful technique providing critical information to the treating interventional radiologist, without additional nephrotoxic contrast or ionizing radiation.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, et al. (2011) Global cancer statistics. CA 61(2):69–90PubMed Jemal A, Bray F, Center MM, et al. (2011) Global cancer statistics. CA 61(2):69–90PubMed
2.
go back to reference ElSerag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60(5):1767–1775CrossRef ElSerag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60(5):1767–1775CrossRef
5.
go back to reference Waki K, Aikata H, Katamura Y, et al. (2010) Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol 25(3):597–604CrossRefPubMed Waki K, Aikata H, Katamura Y, et al. (2010) Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol 25(3):597–604CrossRefPubMed
6.
go back to reference Hwang J, Kim SH, Kim YS, et al. (2010) Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging 32(3):629–638CrossRefPubMed Hwang J, Kim SH, Kim YS, et al. (2010) Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging 32(3):629–638CrossRefPubMed
7.
go back to reference Yoon JH, Lee EJ, Cha SS, et al. (2010) Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 21(3):348–356CrossRefPubMed Yoon JH, Lee EJ, Cha SS, et al. (2010) Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 21(3):348–356CrossRefPubMed
8.
go back to reference Claudon M, Dietrich CF, Choi BI, et al. (2013) Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver: update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 39(2):187–210CrossRefPubMed Claudon M, Dietrich CF, Choi BI, et al. (2013) Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver: update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 39(2):187–210CrossRefPubMed
9.
go back to reference Albrecht T, Blomley M, Bolondi L, et al. (2004) Guidelines for the use of contrast agents in ultrasound January 2004. Ultraschall Med 25(4):249–256CrossRefPubMed Albrecht T, Blomley M, Bolondi L, et al. (2004) Guidelines for the use of contrast agents in ultrasound January 2004. Ultraschall Med 25(4):249–256CrossRefPubMed
10.
go back to reference Wilson SR, Greenbaum LD, Goldberg BB (2009) Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol 193(1):55–60CrossRefPubMed Wilson SR, Greenbaum LD, Goldberg BB (2009) Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol 193(1):55–60CrossRefPubMed
11.
go back to reference Wilson SR, Jang HJ, Kim TK, Burns PN (2007) Diagnosis of focal liver masses on ultrasonography: comparison of unenhanced and contrast-enhanced scans. J Ultrasound Med 26(6):775–787 (quiz 88–90)PubMed Wilson SR, Jang HJ, Kim TK, Burns PN (2007) Diagnosis of focal liver masses on ultrasonography: comparison of unenhanced and contrast-enhanced scans. J Ultrasound Med 26(6):775–787 (quiz 88–90)PubMed
12.
go back to reference Quaia E, D’Onofrio M, Palumbo A, et al. (2006) Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 16(7):1599–1609CrossRefPubMed Quaia E, D’Onofrio M, Palumbo A, et al. (2006) Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 16(7):1599–1609CrossRefPubMed
13.
go back to reference Meloni MF, Andreano A, Zimbaro F, et al. (2012) Contrast enhanced ultrasound: Roles in immediate post-procedural and 24-h evaluation of the effectiveness of thermal ablation of liver tumors. J Ultrasound 15(4):207CrossRefPubMedPubMedCentral Meloni MF, Andreano A, Zimbaro F, et al. (2012) Contrast enhanced ultrasound: Roles in immediate post-procedural and 24-h evaluation of the effectiveness of thermal ablation of liver tumors. J Ultrasound 15(4):207CrossRefPubMedPubMedCentral
14.
go back to reference Choi D, Lim HK, Lee WJ, et al. (2003) Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent. J Ultrasound Med 22(11):1163–1172PubMed Choi D, Lim HK, Lee WJ, et al. (2003) Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent. J Ultrasound Med 22(11):1163–1172PubMed
15.
go back to reference Morimoto M, Nozawa A, Numata K, et al. (2005) Evaluation using contrast-enhanced harmonic gray scale sonography after radio frequency ablation of small hepatocellular carcinoma: sonographic-histopathologic correlation. J Ultrasound Med 24(3):273–283PubMed Morimoto M, Nozawa A, Numata K, et al. (2005) Evaluation using contrast-enhanced harmonic gray scale sonography after radio frequency ablation of small hepatocellular carcinoma: sonographic-histopathologic correlation. J Ultrasound Med 24(3):273–283PubMed
16.
go back to reference Kim CK, Choi D, Lim HK, et al. (2005) Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol 56(1):66–73CrossRefPubMed Kim CK, Choi D, Lim HK, et al. (2005) Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol 56(1):66–73CrossRefPubMed
17.
go back to reference Ding H, Kudo M, Onda H, et al. (2001) Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 221(3):721–730CrossRefPubMed Ding H, Kudo M, Onda H, et al. (2001) Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 221(3):721–730CrossRefPubMed
18.
go back to reference Kim TK, Khalili K (2015) Local ablation therapy with contrast-enhanced ultrasonography for hepatocellular carcinoma: a practical review. 34(4):235–245 Kim TK, Khalili K (2015) Local ablation therapy with contrast-enhanced ultrasonography for hepatocellular carcinoma: a practical review. 34(4):235–245
19.
20.
go back to reference Dohmen T, Kataoka E, Yamada I, et al. (2012) Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma. Intern Med 51:1–7CrossRefPubMed Dohmen T, Kataoka E, Yamada I, et al. (2012) Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma. Intern Med 51:1–7CrossRefPubMed
21.
go back to reference Guibal A, Bertin C, Egels S, et al. (2013) Contrast-enhanced ultrasound (CEUS) follow-up after radiofrequency ablation or cryoablation of focal liver lesions: treated-area patterns and their changes over time. Eur Radiol 23(5):1392–1400CrossRefPubMed Guibal A, Bertin C, Egels S, et al. (2013) Contrast-enhanced ultrasound (CEUS) follow-up after radiofrequency ablation or cryoablation of focal liver lesions: treated-area patterns and their changes over time. Eur Radiol 23(5):1392–1400CrossRefPubMed
22.
go back to reference Wilson SR, Burns PN, Wilkinson LM, Simpson DH, Muradali D (1999) Gas at abdominal US: appearance, relevance, and analysis of artifacts. Radiology 210(1):113–123CrossRefPubMed Wilson SR, Burns PN, Wilkinson LM, Simpson DH, Muradali D (1999) Gas at abdominal US: appearance, relevance, and analysis of artifacts. Radiology 210(1):113–123CrossRefPubMed
23.
go back to reference Yu H, Jang HJ, Kim TK, et al. (2010) Pseudoenhancement within the local ablation zone of hepatic tumors due to a nonlinear artifact on contrast-enhanced ultrasound. AJR Am J Roentgenol 194(3):653–659CrossRefPubMed Yu H, Jang HJ, Kim TK, et al. (2010) Pseudoenhancement within the local ablation zone of hepatic tumors due to a nonlinear artifact on contrast-enhanced ultrasound. AJR Am J Roentgenol 194(3):653–659CrossRefPubMed
Metadata
Title
Role of contrast-enhanced ultrasound (CEUS) in evaluation of thermal ablation zone
Authors
Ilya Lekht
Mittul Gulati
Megha Nayyar
Michael D. Katz
Ramon Ter-Oganesyan
Mary Marx
Steven Y. Cen
Edward Grant
Publication date
01-08-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 8/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0700-4

Other articles of this Issue 8/2016

Abdominal Radiology 8/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine